Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Md Shahjalal has a total of 106 co-authors. Here are the top co-authors by number of shared publications:

  • Rashidul Alam Mahumud

    Faculty of Medicine and Health, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia

    11 shared publications
  • Padam Kanta Dahal

    School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, Australia

    7 shared publications
  • Ahmed Hossain

    6 shared publications
  • Parvez Mosharaf

    School of Business, Faculty of Business, Education, Law and Arts University of Southern Queensland Toowoomba Queensland Australia

    6 shared publications
  • Mohammad Delwer Hossain Hawlader

    Department of Public Health, North South University, Dhaka, Bangladesh

    5 shared publications
  • Mohammad Morshad Alam

    Department of Public Health, North South University, Dhaka, Bangladesh

    5 shared publications

Latest Publications

  • Open Access

    Catastrophic out-of-pocket healthcare expenditures among cancer patients receiving systemic therapy and/or radiation therapy in Bangladesh

    by Md. Shahjalal, Khorshed Alam, Padam Kanta Dahal, Yifu Chen, Ahmed Hossain, Rashidul Alam Mahumud

  • Cancer Burden in Bangladesh: Insights From National Institute of Cancer Research & Hospital, 2014-2020

    by Shahjalal, Padam Kanta Dahal, Arifur Rahman, Sarah Tahera Mahmud, Maheen Kamran, Shabbir Ahmed, Mohammad Delwer Hossain Hawlader, Edward Christopher Dee, Jabed Iqbal, Rashidul Alam Mahumud

    PURPOSE: Bangladesh, a lower-middle–income country in South Asia, faces a rapidly rising cancer burden. In the absence of a population-based cancer registry (PBCR), monitoring national patterns remains challenging and constrains evidence-informed policymaking. We analyzed temporal trends in cancer distribution at the country's largest national cancer hospital to inform priorities for a cancer control strategy. METHODS: We conducted a retrospective analysis of 82,209 histologically and/or clinically confirmed cancer cases diagnosed or treated at the National Institute of Cancer Research & Hospital, between January 2014 and December 2020. Demographic and clinical data were extracted from hospital records, and cancers were grouped according to their primary anatomic site. Annual distributions and sex-specific patters of the 10 most common cancers were examined, and temporal changes were illustrated using trend diagrams. RESULTS: Over 7 years, the most common cancers were of the respiratory system (19.6%-22.5%), digestive organs (18.8%-22.8%), and breast (12%-14.9%). Comparison between 2014 and 2020 revealed notable increases in the proportion of digestive organ cancers (+3.6%), hematopoietic and reticuloendothelial malignancies (+1%), and breast cancer (+0.8%), whereas respiratory cancers (–2.3%), lymph node cancers (–1.1%), and bone and cartilage cancers (–1%) decreased. A marked spike in female genital cancers was observed in 2015 (11.84% v 9.9% average across other years). Findings should be interpreted in the context of hospital-based case mix and referral patterns. CONCLUSION: In this large tertiary cancer hospital in Bangladesh, respiratory system, digestive organ, and breast cancers represented the highest burden, with rising proportions of proportional increases in digestive, hematopoietic, and breast cancers and declines in respiratory and lymph node cancers, provide early signals of an evolving cancer landscape. While not population-representative, these trends highlight the urgent need to establish government-supported PBCRs in well-defined subnational regions to inform effective cancer control strategies for Bangladesh.

  • Open Access

    Assessing inequalities in health utility scores among cancer patients undergoing systemic and radiation therapy

    by Rashidul Alam Mahumud, Padam Kanta Dahal, Shahjalal

    Cancer remains a leading cause of morbidity and mortality worldwide, with low- and middle-income countries like Bangladesh facing a dual burden of rising i

  • Open Access

    Shared decision-making in cancer care in Bangladesh: evidence from a resource-constrained setting

    by M Shahjalal, Rushabh H. Doshi, Shriya K. Garg, Kathleen Buford Cartmell, Edward Christopher Dee

    Section Background Shared decision-making (SDM) is a key component of patient-centered cancer care; however, its implementation remains poorly understood in resource-limited settings like Bangladesh. The purpose of this survey is to assess the prevalence of SDM, identify its associated factors, and evaluate its impact on patient satisfaction within this context. AbstractSection Methods We conducted a cross-sectional survey using convenience sampling between May and July 2024 at a tertiary care specialized cancer hospital in Bangladesh. Eligible participants were adult patients with cancer who had received at least two cycles of chemotherapy or radiation therapy and had the physical and decisional capacity to participate. Chi-square tests assessed bivariate associations, and multivariable logistic regression, adjusted for age, education, and treatment modality, identified independent predictors of SDM participation. AbstractSection Results Among 231 participants (mean [SD] age, 51.6 [13.2] years), 55% were women and 91% were not in formal employment. Overall, 32% of patients reported participating in SDM, whereas 59% expressed a preference for it. Patients with no formal education had 85% lower odds of participating in SDM compared to those with schooling (adjusted odds ratio [AOR], 0.15; 95% confidence interval [CI] 0.06–0.38; P < 0.001). Compared to the youngest group, middle-aged patients had 89% lower odds of participating in SDM (AOR, 0.11; 95% CI 0.04–0.31; P < 0.001), and older patients had 95% lower odds (AOR, 0.05; 95% CI 0.01–0.18; P < 0.001). Working patients had over four times the odds of engaging in SDM compared to non-working patients (AOR, 4.24; 95% CI 2.25–10.17; P = 0.001). Actual involvement in SDM, desire for additional information, and preferred decision-making role were significantly associated with satisfaction (P < 0.001 for all). AbstractSection Conclusions The significant disconnect between patients' high preference for and low participation in SDM highlights a critical gap in patient-centered oncology care in Bangladesh. Systemic barriers, such as severe time constraints and low health literacy, must be addressed through targeted interventions, including clinician training and the development of low-literacy decision aids, to advance equitable cancer care.


  • Open Access

    The Invisible Costs of Cancer Treatment: Quantifying Non‐Medical Economic Consequences for Cancer Survivors Undergoing Systemic and Radiation Therapies

    by Shahjalal, Padam Kanta Dahal, Parvez Mosharaf, Yifu Chen, Mohoua Azmary, Edward Christopher Dee, Khorshed Alam, Rashidul Alam Mahumud

    Background: The non‐medical economic consequences of cancer on individuals and families in low‐ and middle‐income countries, including Bangladesh, remain poorly quantified. This study measures the non‐medical economic consequences of cancer survivors and their families, including sacrifices in essential family consumption, social participation and family members' schooling. Methods: We conducted a cross‐sectional survey between January and May 2022, involving 607 adult patients receiving cancer treatment at two tertiary specialised cancer hospitals in Bangladesh. Participants reported any occurrence of non‐medical economic consequences: reduction in essential goods (REG) consumption, avoidance of social events (ASE) and cessation of schooling (CS) of family members. We used a multivariable logistic regression model to assess the associations between each non‐medical economic consequence and clinical and socioeconomic factors. Additionally, we fitted a Poisson regression to model the count of non‐medical economic consequence events as a function of disease stage and relevant covariates. Results: Overall, 39% of patients reported REG, 36% ASE, and 38% CS. After adjusting for co‐variates, advanced cancer (stage IV) was a significant predictor of non‐medical economic consequence (REG: OR = 5.58, 95% CI 0.99–31.44, p = 0.051; ASE: 11.35, 1.81–71.07, p = 0.009; SS: 101.56, 2.47–4173.90, p = 0.015) compared with early cancer (stage I). Compared with the highest‐income families, patients from low‐ and lower‐middle‐income families had significantly higher odds of experiencing all outcomes (REG: OR = 7.57, 3.01–19.06, p < 0.001 and 7.23, 1.81–28.89, p = 0.005; ASE: 10.21, 3.81–27.36, p < 0.001 and 17.99, 4.26–75.96, p < 0.001; CS: 11.37, 3.23–40.00, p < 0.001 and 12.58, 1.90–83.19, p = 0.009). Employed patients were also at markedly higher risk, with substantially increased odds of REG (18.27 times), ASE (41.01 times) and CS (72.34 times) compared with non‐employed patients (all p < 0.01). Conclusion: Cancer treatment in Bangladesh imposes substantial and inequitable non‐medical economic consequences, disproportionately affecting patients with advanced‐stage cancer, lower‐income families and those in active employment. Policymakers may prioritise strengthening early cancer detection programs, expanding targeted financial protection schemes and introducing workplace and educational support mechanisms to safeguard family welfare and promote more equitable outcomes during cancer treatment.


  • Open Access

    Assessing the Clinical Effectiveness of Radioimmunotherapy with Combined Radionuclide/Monoclonal Antibody Conjugates in Cancer Treatment: Insights from Randomised Clinical Trials

    by Yifu Chen, Padam Kanta Dahal, Parvez Mosharaf, Shahjalal, Rashidul Alam Mahumud

    Background: Despite the development of advanced cancer therapies, achieving cancer eradication remains challenging. Radioimmunotherapy (RIT) is an innovative approach that combines radionuclides with monoclonal antibodies targeting tumour-associated antigens or those expressed by the tumour microenvironment. Over the past two decades, RIT has been extensively researched, along with two RIT products—90Y-ibritumomab tiuxetan and 131I-tositumomab. However, despite its demonstrated efficacy in non-solid tumours, RIT’s clinical use remains limited, and its effectiveness in solid tumours is inconclusive. This study aimed to analyse randomised controlled trials (RCTs) to evaluate the overall clinical effectiveness of RIT across different cancer types and its impact on treatment outcomes. Methods: A systematic search of PubMed, EMBASE, Scopus, CENTRAL, and Google Scholar was conducted from January 2000 to October 2024 in accordance with PRISMA guidelines and the PICOS framework. Studies were included if they were RCTs evaluating RIT for cancer treatment and reported treatment outcomes such as overall survival (OS), progression-free survival (PFS), disease-free survival, or time to progression (TTP). Data extraction was performed using a standardised Excel form, and study quality was assessed with the Joanna Briggs Institute Critical Appraisal Tool for RCTs. A narrative synthesis of the data was complemented by meta-analyses where feasible, particularly for progression- and survival-related endpoints. Results: Out of 2241 records identified, 20 RCTs encompassing approximately 3562 patients were included. The majority of trials focused on non-solid tumours, particularly non-Hodgkin’s lymphoma (NHL), while a smaller subset evaluated solid tumours such as lung, pancreatic, ovarian, and prostate cancers. Most non-solid tumour studies employed 90Y-ibritumomab tiuxetan or 131I-tositumomab, targeting the CD20 antigen, whereas limited evidence exists for RIT efficacy in solid tumours. Meta-analysis of progression-related outcomes yielded a pooled hazard ratio (HR) of 0.48 (95% CI: 0.39–0.59), indicating a 52% reduction in the risk of progression. In contrast, overall survival outcomes were more variable, with a pooled OS HR of 0.80 (95% CI: 0.60–1.07). Adverse events, predominantly haematological and nonhaematological toxicities, were common yet generally reversible. The findings suggest that RIT, especially when used as part of combination regimens, significantly improves treatment outcomes in non-solid tumours but has an inconsistent effect in solid tumour settings. Conclusions: The results underscore the clinical promise of RIT in treating non-solid tumours like NHL, where combination regimens yield superior outcomes compared to monotherapy. However, the inconclusive evidence in solid tumours highlights the need for further large-scale, well-designed RCTs to define the optimal use, dosing, and patient selection for RIT in these settings. Additionally, standardisation in outcome reporting and longer follow-up periods are essential for more accurate economic and clinical assessments. Overall, RIT represents a valuable therapeutic modality, yet its integration into cancer treatment regimens should be guided by further research aimed at mitigating toxicity and optimising combination strategies.


  • Cancer driven direct medical costs in Bangladesh: Evidence from patient perspective

    by Shahjalal, Parvez Mosharaf, Padam Kanta Dahal, Mohammad Enamul Hoque, Rashidul Alam Mahumud


  • Open Access

    Emerging burden of post-cancer therapy complications on unplanned hospitalisation and costs among Australian cancer patients: a retrospective cohort study over 14 years

    by Rashidul Alam Mahumud, Shahjalal, Padam Kanta Dahal, Parvez Mosharaf, Sabuj Kanti Mistry, Kamrun Nahar Koly, Sujana Haque Chowdhury, Andre M. N. Renzaho, Jeff Gow, Khorshed Alam, et al.

    Cancer treatment using systemic therapy and radiotherapy may cause post-therapy complications, resulting in increased unplanned hospitalisation. The evidence on such complications, their impact on unplanned hospitalisations, and associated costs is scant in Australia. We aimed to estimate the prevalence of post-therapy complications, evaluate their impact on unplanned hospitalisation, length of stay (LOS) and investigate the associated medical costs. A retrospective cohort study was conducted among 8,633 cancer patients (1.03 million emergency hospital admissions) in Victoria, Australia from July 2006 to June 2020, from the Australian healthcare system perspective. Multivariate generalised linear regression models were employed to estimate the adjusted association between post-therapy complications and clinical characteristics with hospital LOS and associated hospitalisation medical costs. Approximately 52% of patients were male with an average patient age of 59.9 years. Annually, post-therapy complications leading to unplanned hospitalisations increased by 7.25%, outpacing the growth in overall hospitalisation admissions, which was 5.66% for overall hospitalisation admissions. A significant proportion of patients (71%) experienced multiple complications, with the most common being anemia (26%), sepsis (15%), nausea and vomiting (14%), and neutropenia (11%). Patients undergoing combined systemic and radiotherapy exhibited higher odds of post-therapy complications (OR = 8.24, 95%CI: 7.48 to 9.08) compared with those who only received systemic therapy. Mean hospital stay among patients who experienced post-therapy complications was 2.23 days per admission (360 days per patient), an extra 1.72 days per admission [95%CI: 1.68 to 1.76; 354 days per patient, 95%CI: 336 to 371 days] longer than patients without complications (0.51 days per admission and 6.48 days per patients). Overall, per-admission medical hospitalisation costs among patients with post-therapy complications were $8,791 higher than for patients who did not experience complications ($11,418 vs. $2,627 per admission, 95%CI: $8,685 to $8,897). Per-patient costs for unplanned hospitalisation due to post-therapy complications were significantly $1.82 million higher among patients than those without complications ($1.86 million vs. $33,599 per patient, 95%CI: $1.71 million to $1.94 million). The cost and hospitalisation stay (in days) varied by the type of therapy and cancer type. The study results indicate that post-therapy complications in cancer patients varied by the type of cancer and increased over the study period, leading to longer unplanned hospital stays and higher hospitalisation medical costs. The results highlight the need for better-customized treatment delivery strategies to address this burden and optimise resources in cancer care.


  • Open Access

    Association between Mediterranean diet adherence and dyslipidemia among type-2 diabetes mellitus patients in Dhaka, Bangladesh: a hospital-based study

    by Mohammad Morshad Alam, Nuzhat-E.-Nusrat Nureen, Sutapa Bhowmik, Shah Wazed, Kazi Lutfar Rahman, Mohammad Delwer Hossain Hawlader, Shahjalal


  • Open Access

    Economic Burden of Healthcare Services on Cancer Survivors in Bangladesh

    by Shahjalal, Padam Kanta Dahal, Parvez Mosharaf, Mohammad Morshad Alam, Mohammad Delwer Hossain Hawlader, Rashidul Alam Mahumud

    Background: Cancer is a critical public health issue that imposes a considerable economic burden, especially in low‐resource countries. In Bangladesh, there has been a noticeable lack of research focusing on the economic burden associated with cancer. Aims: This study aimed to examine the economic burden of cancer care and the contributing factors.Methods: This cross‐sectional study included 623 cancer patients. Data were collected between January and May 2022. The magnitude of the economic burden (no burden to extreme burden) was the outcome variable. A logistic regression model was performed to determine the associated factors of the economic burden of cancer.Results: Overall, 34% of cancer survivors experienced extreme economic burden due to treatment costs. Patients with prostate (relative risk ratio, RRR = 23.24; 95% confidence interval, CI: 1.97, 273.70), bone (RRR = 5.85; 95% CI: 1.10, 31.04), and liver cancer (RRR = 4.94; 95% CI: 1.29, 18.9) reported significantly higher extreme economic burden compared to patients with other cancers. The economic burden was significantly higher for patients diagnosed with Stage III (RRR = 38.69; 95% CI: 6.17, 242.72) and Stage IV (RRR = 24.74; 95% CI: 3.22, 190.11) compared to Stage 0. Patients from low‐income households suffered from nine times more extreme burden (RRR = 8.85; 95% CI: 4.05, 19.36) compared with those from high‐income households.Conclusion: Our study found a disproportionately high economic burden among patients with cancer, across disease sites, stages, and income quintiles. The burden was significantly higher among patients with prostate, bone, and liver cancer, and those diagnosed with advanced stage. The findings underscore the importance of early cancer detection before metastasis which may lead to more efficient treatment, avoid disease progression, lower disease management costs, and better health outcomes. Patients from low‐income households experience an extreme economic burden due to cancer, highlighting the need for affordable healthcare services, financial support, and healthcare subsidies.